Market Eyes LiveUniversal Health Services, Inc. Class B (UHS) Stock Rating & Analysis
MELANY's data-driven read on Universal Health Services, Inc. Class B · Services-General Medical & Surgical Hospitals, Nec.
Universal Health Services Inc provides healthcare through behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, it operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supporting outpatient facilities. Operations are concentrated in the US, especially Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), with some exposure to the UK behavioral health market (6% of 2025 sales).
Why UHS scores 61/100
MELANY scores Universal Health Services, Inc. Class B 61/100 by weighing eight factors. Here is how UHS breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 7.2x vs sector 22.0x median
Margins, returns on capital, and balance-sheet strength.
- Gross margin 45%
- ROE 21%
Direction and relative strength of the recent share-price trend.
- Price +11.4% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for UHS
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Universal Health Services, Inc. Class B sits in the Healthcare sector theme, which MELANY currently rates 51/100 for strength. Theme strength feeds UHS's momentum and catalyst factors above.
Tracking UHS
Universal Health Services, Inc. Class B rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add UHS to your watchlist and get alerted the moment the rating changes.
How MELANY rates UHS
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Universal Health Services, Inc. Class B's 61/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about UHS
Is Universal Health Services, Inc. Class B (UHS) a buy?
As of 2026-08-24, MELANY rated Universal Health Services, Inc. Class B Hold with a composite score of 61/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Universal Health Services, Inc. Class B's MELANY score?
Universal Health Services, Inc. Class B (UHS) has a MELANY composite score of 61/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the UHS stock rating calculated?
MELANY scores UHS from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Universal Health Services, Inc. Class B stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Universal Health Services, Inc. Class B (UHS) Hold with a composite of 61/100 as of 2026-08-24. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the UHS stock price forecast?
MELANY does not publish price targets or forecasts for UHS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 61/100 across eight factors for Universal Health Services, Inc. Class B, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is UHS stock overvalued or undervalued?
MELANY's valuation factor currently reads 81/100 for Universal Health Services, Inc. Class B, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives UHS's read.
What price should I buy UHS at?
MELANY is not flagging a fresh entry for UHS at its current Hold rating, so there is no entry zone to publish right now. Watchlisting UHS in the free app gets you alerted the moment that changes.
What are the risks of buying UHS stock?
The top risks MELANY currently flags for Universal Health Services, Inc. Class B: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Universal Health Services, Inc. Class B a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 58/100 for Universal Health Services, Inc. Class B, and earnings track record, at 66/100. The 61/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will UHS stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 49/100 for UHS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this UHS rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-24. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores UHS continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
UHS's live rating and alerts are free either way. The app is our flagship.